Anticoagulant Regimen for Patients with Thrombotic Events

Introduction to Anticoagulation Therapy

The American College of Cardiology recommends direct oral anticoagulants (DOACs) as the first-line anticoagulant therapy for patients with atrial fibrillation, deep vein thrombosis, or pulmonary embolism, with specific dosing based on the indication and patient characteristics 1, 2

The American College of Cardiology suggests using the CHA₂DS₂-VASc score to determine stroke risk in patients with atrial fibrillation, with 1 point each for congestive heart failure, hypertension, age 65-74 years, diabetes, vascular disease, and female sex, and 2 points each for age ≥75 years and prior stroke/TIA/thromboembolism 3
Anticoagulation is recommended for patients with a CHA₂DS₂-VASc score ≥2 in men or ≥3 in women 3
Apixaban 5 mg orally twice daily is the preferred DOAC for patients with atrial fibrillation 1

For patients with deep vein thrombosis or pulmonary embolism, the American College of Cardiology recommends anticoagulation therapy, with a duration of 3 months for provoked VTE and indefinite anticoagulation for unprovoked VTE or VTE with chronic risk factors 2
The definition of provoked VTE includes events associated with surgery, trauma, immobilization, pregnancy, or hormonal therapy occurring within 3 months, while unprovoked VTE has no identifiable transient risk factor 2

For patients on anticoagulation for atrial fibrillation or VTE without recent coronary intervention or acute coronary syndrome, the American College of Cardiology recommends stopping all antiplatelet therapy immediately 1, 5, 6, 7
For patients with recent coronary intervention or acute coronary syndrome, the American College of Cardiology suggests stopping aspirin and continuing clopidogrel with a DOAC for 6-12 months, then transitioning to DOAC monotherapy 1, 5

The American College of Cardiology recommends performing a HAS-BLED score at each visit to assess bleeding risk, with 1 point each for hypertension, abnormal renal/liver function, stroke history, bleeding history, labile INR, elderly, and drugs/alcohol 3
A HAS-BLED score ≥3 indicates high bleeding risk, requiring closer monitoring 3
The American College of Cardiology suggests initiating proton pump inhibitor for gastrointestinal protection, optimizing blood pressure control, avoiding NSAIDs and other medications that increase bleeding risk, and monitoring renal function to mitigate bleeding risk 6, 8

For breakthrough VTE on warfarin, the American College of Cardiology recommends switching to low-molecular-weight heparin rather than a DOAC 2
Careful evaluation for underlying conditions and drug-drug interactions is necessary, and re-evaluation is recommended when clinically stable to determine the best course of treatment 2